Chinese herbal medicine for atopic eczema: an overview of clinical evidence.
Gu SX, Zhang AL, Coyle ME, Chen D, Xue CC. Chinese herbal medicine for atopic eczema: an overview of clinical evidence. J Dermatolog Treat 2017;28(3):246-250.
Study type: Overview of systematic reviews and RCTs 2013-2016 · Added to this library August 23, 2026
What they found
Cochrane review suggests oral CHM may improve health-related quality of life in children with moderate-severe AE; benefit on severity needs higher-quality trials.
Why it matters
The quality-of-life finding maps directly onto what parents report first (sleep, mood, the house calming down) before SCORAD-type scores move — consistent with what families consistently report first: sleep, mood and the household settle before the skin's severity scores move.
Relates to the patterns: Blood Heat · Blood Deficiency / Wind-Dryness
This summary is educational and does not replace care from your child's pediatrician. Evidence tiers matter: a finding in cells or animals is a reason a treatment could work, not proof that it does.
More in Trial lineage
A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema.
Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992;126(2):179-84.
Study type: RCT (double-blind, placebo-controlled, crossover)
What: Great Ormond Street (Hospital for Sick Children, London). 47 children with severe, widespread, non-exudative atopic eczema; 8 weeks active decoction vs 8 weeks placebo in random order, 4-week washout. 37 completed. A *specific prescription formulated for this one presentation* (the ten-herb formula later productised as "Zemaphyte" — Dr Luo Dinghui's formula).
Found: Active treatment superior to placebo and "clinically valuable"; no haematological, renal or hepatic toxicity.
Why it matters: The landmark. Western dermatology's first double-blind evidence that TCM herbs work in pediatric eczema — and it worked because the formula was matched to a pattern, not to the diagnosis "eczema."
Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis.
Sheehan MP, Rustin MH, Atherton DJ, Buckley C, Harris DW, Brostoff J, Ostlere L, Dawson A. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992;340(8810):13-7.
Study type: RCT (double-blind, placebo-controlled, crossover)
What: Royal Free Hospital. 40 adults with longstanding, refractory, widespread AD; same ten-herb daily decoction vs placebo, 2 months each, 4-week washout.
Found: Geometric mean erythema score 12.6 (active) vs 113 (placebo); surface damage 11.3 vs 111.0; ratio CI 0.04-0.22 (p<0.0005). 20 of 31 preferred the active phase vs 4 placebo (p<0.02). Itch improved (p<0.001), sleep trended (p=0.078). No side-effects; decoction unpalatable.
Why it matters: A ~90% reduction in erythema scores in a Lancet double-blind trial is the number to quote when a pediatrician asks "is there any evidence." Also the adult companion to our pediatric case.
Treatment of atopic eczema with traditional Chinese medicinal plants.
Atherton DJ, Sheehan MP, Rustin MH, Whittle B, Guy G. Treatment of atopic eczema with traditional Chinese medicinal plants. Pediatr Dermatol 1992;9(4):373-5.
Study type: Review / commentary (no abstract indexed)
What: The same group's short review for a pediatric dermatology audience, summarising the London experience.
Why it matters: Useful as the "pediatric dermatology journal took this seriously in 1992" citation; the substance is in [SHEEHAN-1992a/b].
One-year follow up of children treated with Chinese medicinal herbs for atopic eczema.
Sheehan MP, Atherton DJ. One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994;130(4):488-93.
Study type: Human observational (open-label extension, n=37)
What: All 37 trial completers' parents elected to continue. Goal: reach substantial improvement, then taper while holding the gain.
Found: At 12 months 18/37 had ≥90% reduction in eczema activity scores, 5 lesser improvement; 14 withdrew (10 non-response, 4 palatability/preparation). 7 children discontinued treatment without relapse; 16 needed maintenance but only 4 daily. Two children had asymptomatic AST elevations 7-14× normal on one occasion (therapy stopped because eczema was so well controlled), normal 8 weeks later.
Why it matters: This is the paper that describes *our* clinical arc — improve, taper, some children come off entirely. The roughly 50% sustained responder rate and the "taper, don't stop" design are the honest benchmark for what this medicine can do. The AST finding is why we keep liver safety in the frame for any long-course internal formula.